DE19534519A1
(en)
*
|
1995-09-05 |
1997-07-10 |
Desitin Arzneimittel Gmbh |
Sugar or sugar alcohols for use as an anti-epileptic
|
WO2010046726A1
(en)
|
2008-10-20 |
2010-04-29 |
Chemyunion Química Ltda. |
Xylitol esters and ethers applied as alternative emulsifiers, solvents, co-emulsifiers and preservative systems for pharmaceutical and cosmetic products
|
WO2014037832A2
(en)
*
|
2012-09-06 |
2014-03-13 |
Mahesh Kandula |
Compositions and methods for the treatment of epilepsy and neurological diseases
|
CA2873093A1
(en)
|
2012-05-07 |
2013-11-14 |
Cellixbio Private Limited |
Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
|
WO2013167985A1
(en)
|
2012-05-07 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of neurological disorders
|
US9399634B2
(en)
|
2012-05-07 |
2016-07-26 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of depression
|
WO2013168025A1
(en)
|
2012-05-08 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of blood clotting disorders
|
US9522884B2
(en)
|
2012-05-08 |
2016-12-20 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic disorders
|
US9403826B2
(en)
|
2012-05-08 |
2016-08-02 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of inflammatory disorders
|
WO2013168023A1
(en)
|
2012-05-08 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of parkinson's disease
|
US9434704B2
(en)
|
2012-05-08 |
2016-09-06 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological degenerative disorders
|
WO2013168014A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of familial amyloid polyneuropathy
|
WO2013168002A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of neurological conditions
|
WO2013168000A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of severe pain
|
US9346742B2
(en)
|
2012-05-10 |
2016-05-24 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of fibromyalgia pain
|
WO2013168011A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of chronic pain
|
US9242939B2
(en)
|
2012-05-10 |
2016-01-26 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of respiratory disorders
|
US9394288B2
(en)
|
2012-05-10 |
2016-07-19 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of asthma and allergy
|
US9315478B2
(en)
|
2012-05-10 |
2016-04-19 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic syndrome
|
WO2013168005A2
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
|
US9403857B2
(en)
|
2012-05-10 |
2016-08-02 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic syndrome
|
WO2013168001A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of moderate to severe pain
|
WO2013167999A2
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for the treatment of neurologic diseases
|
WO2013168033A1
(en)
|
2012-05-10 |
2013-11-14 |
Mahesh Kandula |
Compositions and methods for treatment of neurologic diseases
|
WO2013175344A2
(en)
|
2012-05-23 |
2013-11-28 |
Mahesh Kandula |
Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
|
US9492409B2
(en)
|
2012-05-23 |
2016-11-15 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of local pain
|
CA2873104A1
(en)
|
2012-05-23 |
2013-11-28 |
Cellixbio Private Limited |
Compositions and methods for the treatment of mucositis
|
CA2873098A1
(en)
|
2012-05-23 |
2013-11-28 |
Cellixbio Private Limited |
Compositions and methods for the treatment of multiple sclerosis
|
WO2013175347A2
(en)
|
2012-05-23 |
2013-11-28 |
Mahesh Kandula |
Compositions and methods for the treatment of respiratory disorders
|
NZ701832A
(en)
|
2012-05-23 |
2016-08-26 |
Cellix Bio Private Ltd |
Compositions and methods for treatment of inflammatory bowel disease
|
US9108942B1
(en)
|
2014-11-05 |
2015-08-18 |
Mahesh Kandula |
Compositions and methods for the treatment of moderate to severe pain
|
WO2014020480A2
(en)
|
2012-08-03 |
2014-02-06 |
Mahesh Kandula |
Compositions and methods for the treatment migraine and neurologic diseases
|
US9624168B2
(en)
|
2012-09-06 |
2017-04-18 |
Cellix Bio Private Limited |
Compositions and methods for the treatment inflammation and lipid disorders
|
WO2014037834A2
(en)
|
2012-09-08 |
2014-03-13 |
Mahesh Kandula |
Compositions and methods for the treatment of inflammation and lipid disorders
|
US9333187B1
(en)
|
2013-05-15 |
2016-05-10 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of inflammatory bowel disease
|
SG11201509782TA
(en)
|
2013-06-04 |
2015-12-30 |
Cellix Bio Private Ltd |
Compositions and methods for the treatment of diabetes and pre-diabetes
|
US9096537B1
(en)
|
2014-12-31 |
2015-08-04 |
Mahesh Kandula |
Compositions and methods for the treatment of mucositis
|
NZ736131A
(en)
|
2014-09-26 |
2019-04-26 |
Cellix Bio Private Ltd |
Compositions and methods for the treatment of epilepsy and neurological disorders
|
EP3201168B1
(en)
|
2014-09-29 |
2020-03-18 |
Cellix Bio Private Limited |
Compounds and compositions for the treatment of multiple sclerosis
|
CA2965449C
(en)
|
2014-10-27 |
2020-11-10 |
Cellix Bio Private Limited |
Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
|
US9173877B1
(en)
|
2014-11-05 |
2015-11-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of local pain
|
US9150557B1
(en)
|
2014-11-05 |
2015-10-06 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of hyperglycemia
|
US9321716B1
(en)
|
2014-11-05 |
2016-04-26 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of metabolic syndrome
|
US9284287B1
(en)
|
2014-11-05 |
2016-03-15 |
Cellix Bio Private Limited |
Compositions and methods for the suppression of carbonic anhydrase activity
|
US9175008B1
(en)
|
2014-11-05 |
2015-11-03 |
Cellix Bio Private Limited |
Prodrugs of anti-platelet agents
|
US9290486B1
(en)
|
2014-11-05 |
2016-03-22 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of epilepsy
|
US10208014B2
(en)
|
2014-11-05 |
2019-02-19 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological disorders
|
US9932294B2
(en)
|
2014-12-01 |
2018-04-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of multiple sclerosis
|
US9206111B1
(en)
|
2014-12-17 |
2015-12-08 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
JP6679616B2
(en)
|
2015-01-06 |
2020-04-22 |
セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited |
Compositions and methods for the treatment of inflammation and pain
|